Clinical Trials Logo

Clinical Trial Summary

There are currently no target therapies approved for treatment of anaplastic thyroid cancer (ATC), leading to a clear need for improving therapy for ATC. This is a single-arm, multicenter study to evaluate the efficacy and safety of HX008 injection in patients with metastatic or locally advanced anaplastic thyroid cancer.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04574817
Study type Interventional
Source Taizhou Hanzhong biomedical co. LTD
Contact Yuankai Shi
Phone 010-87788293
Email syuankai@cicams.ac.cn
Status Not yet recruiting
Phase Phase 2
Start date December 28, 2020
Completion date May 30, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04420754 - Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer Phase 1
Completed NCT02152137 - Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer Phase 2
Active, not recruiting NCT04552769 - Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Phase 2
Active, not recruiting NCT04400474 - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study Phase 2
Completed NCT02688608 - Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Phase 2
Terminated NCT00095693 - Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer Phase 2
Active, not recruiting NCT01240590 - A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) Phase 1/Phase 2
Not yet recruiting NCT05819593 - Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
Active, not recruiting NCT04579757 - Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06374602 - Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer Phase 2
Recruiting NCT06362694 - Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy Phase 2
Withdrawn NCT01701349 - Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer Phase 3
Active, not recruiting NCT03085056 - Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer Early Phase 1
Recruiting NCT01774279 - interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
Terminated NCT00126568 - Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer Phase 2
Completed NCT02244463 - A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer Phase 1/Phase 2
Active, not recruiting NCT05696548 - Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) Phase 2
Terminated NCT00603941 - A Phase 1/2 Study of CS7017, an Oral PPARĪ³ Agonist, in Combination With Paclitaxel Phase 1/Phase 2
Completed NCT00280852 - Review of Multimodality Management of Anaplastic Thyroid Cancer N/A
Recruiting NCT04238624 - Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer Phase 2